Outcome of Board Meeting
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.1 pts more than Nifty Microcap 250 and 2.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Checkpoint Trends Limited's board approved standalone unaudited results for the quarter and half-year ended September 30, 2025. Net revenue from operations surged to ₹10,859.42 lakhs in Q2 FY26 (from ₹500 lakhs in Q2 FY25), taking H1 FY26 revenue to ₹12,030.69 lakhs (vs ₹1,500 lakhs in H1 FY25). Profit before tax for H1 FY26 stood at ₹188.52 lakhs versus a marginal loss of ₹0.53 lakh a year earlier, while PAT turned positive at ₹141.03 lakhs (vs a small loss). Revenue is split across two new segments — Tobacco Products (₹3,567 lakhs) and FMCG Products (₹8,439 lakhs). The auditor (L K Ajmera & Associates) issued an unmodified review opinion. Total assets ballooned to ₹14,063.95 lakhs (from ₹65.25 lakhs), largely driven by trade receivables (₹13,906 lakhs) and trade payables (₹13,803 lakhs). Other equity remains negative at ₹(349.98) lakhs, though improving from ₹(491.01) lakhs. Operating cash flow was positive at ₹11.84 lakhs.
Sharp top-line growth and a swing to profitability are positive for shareholders, but the simultaneous surge in receivables and payables alongside a still-negative net worth (other equity) needs scrutiny. The trading window reopens from November 15, 2025, which is also when insider activity may resume.